Novartis AG (NOVNZ.XC)
| Previous close | 96.93 |
| Open | 96.99 |
| Bid | 97.37 x N/A |
| Ask | 97.37 x N/A |
| Day's range | 96.21 - 97.49 |
| 52-week range | 81.63 - 100.96 |
| Volume | |
| Avg. volume | 426,458 |
| Market cap | 197.154B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 22.49 |
| EPS (TTM) | 4.33 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.30 (3.40%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
ZacksIs a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
ReutersPharma aims to deliver personalized cancer therapies more quickly
Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient's disease course. These treatments known as CAR-T therapies are used for the sickest patients for whom standard treatments have failed. Gilead Sciences, Novartis, Johnson & Johnson, and Bristol Myers Squibb have made billions from their treatments, which can extend lives by months or years for patients with aggressive advanced cancers.
ZacksThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
